Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET randomized clinical trial
JAMA May 23, 2019
Vincent JL, et al. – In this investigation involving patients with sepsis-associated coagulopathy, researchers determined the impact of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality. The study was completed by 800 of 816 randomized patients, who were included in the full analysis set. Overall, the administration of human recombinant thrombomodulin did not significantly reduce 28-day all-cause mortality vs placebo in patients with sepsis-associated coagulopathy.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries